Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Minerva Neurosciences, Inc. (NASDAQ: NERV).

Full DD Report for NERV

You must become a subscriber to view this report.


Recent News from (NASDAQ: NERV)

Premarket Gainers as of 9:05 am (5/17/2018)
BLNK +16% . More news on: Blink Charging Co., Minerva Neurosciences, Loxo Oncology, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 17 2018 09:19
Minerva Neurosciences' roluperidone shows treatment effect in schizophrenia patients; shares ahead 13% premarket
Minerva Neurosciences (NASDAQ: NERV ) announces that The Journal of Clinical Psychiatry has published online results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101). The results also demonstrated that cognitive improvements correlate ...
Source: SeekingAlpha
Date: May, 17 2018 09:12
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has published...
Source: Thomson Reuters ONE
Date: May, 17 2018 08:00
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has publish...
Source: GlobeNewswire
Date: May, 17 2018 08:00
Minerva Neurosciences' (NERV) CEO Dr. Remy Luthringer on Q1 2018 Results - Earnings Call Transcript
Minerva Neurosciences, Inc. (NERV) Q1 2018 Earnings Conference Call May 03, 2018 08:30 AM ET Executives William Boni - Vice President, Investor Relations and Corporate Communications Dr. Remy Luthringer - Executive Chairman and Chief Executive Officer Geoff Race - Executive Vice ...
Source: SeekingAlpha
Date: May, 03 2018 11:19
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the q...
Source: GlobeNewswire
Date: May, 03 2018 07:30
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busine...
Source: GlobeNewswire
Date: April, 26 2018 08:30
Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback
A nalysis focus: Acadia Today we will discuss Acadia Pharmaceuticals (ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. The CNN article notes that there were always safety concerns with the drug and that some committee mem...
Source: SeekingAlpha
Date: April, 10 2018 08:00
Minerva commences mid-stage study of MIN-117 in MDD; shares up 2%
Thinly traded micro cap Minerva Neurosciences ( NERV +2.2% ) is up, albeit on light volume, on the heels of its announcement that the first patient has been screened in its Phase 2b clinical trial assessing MIN-117 in patients with major depressive disorder (MDD). More news on: Miner...
Source: SeekingAlpha
Date: April, 09 2018 10:16
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Multi-center trial to enroll approximately 324 patients at approximately 40 clinical sites in U.S. and Europe WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to...
Source: Thomson Reuters ONE
Date: April, 09 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-176.757.407.556.551494,470
2017-02-0310.8010.8010.8510.509,797
2017-02-0210.4510.7010.8510.158486,001
2017-02-0110.6510.5010.9010.3099,453
2017-01-3110.2510.6010.7510.00329,024

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2528,41672,34039.2812Short
2018-05-2451,415147,15034.9405Cover
2018-05-2340,398136,66429.5601Cover
2018-05-2235,73769,81451.1889Short
2018-05-2142,16097,69643.1543Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NERV.


About Minerva Neurosciences, Inc. (NASDAQ: NERV)

Logo for Minerva Neurosciences, Inc. (NASDAQ: NERV)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: NERV)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 24 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 24 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 22 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 12 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 12 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 21 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: NERV)

      Daily Technical Chart for (NASDAQ: NERV)


      Stay tuned for daily updates and more on (NASDAQ: NERV)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: NERV)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NERV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of NERV and does not buy, sell, or trade any shares of NERV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/